Alirocumab
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1076 publications
Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis.
Journal: American journal of therapeutics
Published: June 24, 2026
Drugs for hypercholesterolemia.
Journal: The Medical letter on drugs and therapeutics
Published: June 01, 2026
Comparison chart: Some non-statin lipid-lowering drugs.
Journal: The Medical letter on drugs and therapeutics
Published: June 01, 2026
PCSK9 inhibitors conquer primary prevention: the VESALIUS-CV study.
Journal: European heart journal supplements : journal of the European Society of Cardiology
Published: May 08, 2026
Potential beneficial effect of treatment with PCSK9 inhibitors on vascular endothelial dysfunction: a systematic review and meta-analysis.
Journal: Expert review of clinical pharmacology
Published: May 06, 2026
Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis.
Journal: JAMA network open
Published: May 05, 2026
Review: natural compounds as PCSK9 inhibitors for antiviral therapy.
Journal: Archives of microbiology
Published: May 03, 2026
Lerodalcibep (Lerochol) for hypercholesterolemia.
Journal: The Medical letter on drugs and therapeutics
Published: May 02, 2026
Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in peripheral artery disease-a systematic review and meta-analysis.
Journal: Current medical research and opinion
Published: April 30, 2026
Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment.
Journal: Journal of the American Heart Association
Published: April 22, 2026
Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy.
Journal: Journal of the American Heart Association
Published: April 07, 2026
Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.
Journal: Future oncology (London, England)
Published: April 06, 2026
Last Updated: 06/30/2026